Seeking Alpha·Sep 16, 2026
Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptBruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bruker's top-line recovery is underway, with 2026Q2 revenue up 5.2% YoY and gross margin improving to 49.6%, yet operating leverage remains elusive as operating margin swung to -7.8% and net income fell to a -$52.0M loss. The balance sheet has deleveraged nota...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth rebounded to 5.2% YoY in 2026Q2 with gross margin at 49.6%, but operating margin fell to -7.8% and net income swung to a -$52.0M loss, reflecting persistent cost pressures.
Bruker's advanced instruments enable exploration at molecular, cellular, and microscopic levels, driving demand in research and diagnostics.
Despite stock decline, Bruker has demonstrated revenue growth and robust free cash flow, indicating financial health.
Analysts suggest Bruker could see a stock re-rating toward $80 if margins improve, offering upside potential.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.49+27.3% vs $0.38 | $839M-1.8% vs $854M |
Q2 2026 May 6, 2026 | $0.31+34.8% vs $0.23 | $823M+3.5% vs $796M |
Q1 2026 Feb 12, 2026 | $0.59-9.2% vs $0.65 | $977M+1.6% vs $962M |
Q4 2025 Nov 3, 2025 | $0.60+81.8% vs $0.33 | $861M-10.8% vs $965M |
Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
[url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences:Wells Fargo 21st Annual Heal
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Wells Fargo 21st Annual Healthcare Conference in Boston, MA Wednesday, September 9, 2026 at 8:00 a.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York City Wednesday, September 16, 2026, at 10:45 a.m. Eastern Time Bank of America Global Healthcare Conference in London, UK Tuesday, September 22, 2026, at 6:45 a.
Benchmark BRKR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bruker Corporation (BRKR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $61.21 | $9.32B | -408.07 | 2.08% | -0.25% | -0.4% | 0.25% | |
| $425.74 | $31.84B | 39.57 | 6.99% | 3.58% | 1.88% | — | |
| $59.30 | $13.82B | 33.89 | -2.61% | -2.77% | -1.87% | — | |
| $55.95 | $16.9B | 32.16 | -17.48% | 12.38% | 8.51% | — | |
| $167.25 | $47.24B | 36.60 | 6.73% | 19.53% | 20.47% | — | |
| $658.52 | $244.72B | 37.12 | 3.91% | 15.06% | 13.33% | — |
Bruker Corporation (BRKR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bruker Corporation (BRKR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 4, 2026·SEC
Jul 30, 2026·SEC
Get notified when BRKR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bruker Corporation (BRKR) stock FAQ — growth, dividends, profitability & financials explained
Bruker Corporation (BRKR) reported $3.50B in revenue for fiscal year 2025. This represents a 5310% increase from $64.7M in 1999.
Bruker Corporation (BRKR) grew revenue by 2.1% over the past year. Growth has been modest.
Bruker Corporation (BRKR) reported a net loss of $71.2M for fiscal year 2025.
Yes, Bruker Corporation (BRKR) pays a dividend with a yield of 0.25%. This makes it attractive for income-focused investors.
Bruker Corporation (BRKR) has a return on equity (ROE) of -0.4%. Negative ROE indicates the company is unprofitable.
Bruker Corporation (BRKR) generated $93.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
